Insider Selling: Penumbra (NYSE:PEN) EVP Sells 600 Shares of Stock

Penumbra, Inc. (NYSE:PEN) EVP Johanna Roberts sold 600 shares of the business’s stock in a transaction dated Wednesday, October 1st. The stock was sold at an average price of $249.70, for a total transaction of $149,820.00. Following the completion of the sale, the executive vice president owned 64,257 shares in the company, valued at $16,044,972.90. This represents a 0.93% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Johanna Roberts also recently made the following trade(s):

• On Tuesday, September 2nd, Johanna Roberts sold 600 shares of Penumbra stock. The stock was sold at an average price of $270.58, for a total transaction of $162,348.00.
• On Monday, August 11th, Johanna Roberts sold 600 shares of Penumbra stock. The stock was sold at an average price of $238.94, for a total transaction of $143,364.00.

Penumbra Price Performance

Penumbra stock opened at $256.05 on Friday. Penumbra, Inc. has a 52 week low of $190.08 and a 52 week high of $310.00. The company has a quick ratio of 4.04, a current ratio of 6.75 and a debt-to-equity ratio of 0.02. The firm’s 50-day simple moving average is $257.64 and its 200 day simple moving average is $262.85. The firm has a market capitalization of $9.99 billion, a PE ratio of 68.10, a P/E/G ratio of 2.31 and a beta of 0.41.

Penumbra (NYSE:PEN) last released its quarterly earnings data on Tuesday, July 29th. The company reported $0.86 EPS for the quarter, topping the consensus estimate of $0.81 by $0.05. Penumbra had a net margin of 11.54% and a return on equity of 11.55%. The business had revenue of $339.46 million for the quarter, compared to analyst estimates of $327.37 million. During the same period in the previous year, the firm earned $0.64 EPS. The business’s revenue for the quarter was up 13.4% compared to the same quarter last year. Penumbra has set its FY 2025 guidance at EPS. On average, equities research analysts predict that Penumbra, Inc. will post 3.67 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Corient Private Wealth LLC increased its stake in shares of Penumbra by 4.1% during the 2nd quarter. Corient Private Wealth LLC now owns 2,335 shares of the company’s stock valued at $599,000 after acquiring an additional 92 shares during the last quarter. Texas Permanent School Fund Corp grew its holdings in shares of Penumbra by 58.7% during the 2nd quarter. Texas Permanent School Fund Corp now owns 25,646 shares of the company’s stock worth $6,582,000 after purchasing an additional 9,491 shares during the period. Osaic Holdings Inc. grew its holdings in shares of Penumbra by 85.7% during the 2nd quarter. Osaic Holdings Inc. now owns 3,287 shares of the company’s stock worth $843,000 after purchasing an additional 1,517 shares during the period. Newbridge Financial Services Group Inc. purchased a new stake in shares of Penumbra during the 2nd quarter worth about $30,000. Finally, State of Wyoming purchased a new stake in shares of Penumbra during the 2nd quarter worth about $64,000. Institutional investors and hedge funds own 88.88% of the company’s stock.

Analysts Set New Price Targets

Several research analysts recently weighed in on PEN shares. Morgan Stanley boosted their target price on shares of Penumbra from $260.00 to $266.00 and gave the company an “equal weight” rating in a research note on Thursday, July 31st. Truist Financial set a $310.00 target price on shares of Penumbra and gave the company a “buy” rating in a research note on Wednesday, July 30th. Robert W. Baird boosted their target price on shares of Penumbra from $283.00 to $285.00 and gave the company an “outperform” rating in a research note on Wednesday, July 30th. Royal Bank Of Canada cut their target price on shares of Penumbra from $330.00 to $325.00 and set an “outperform” rating for the company in a research note on Wednesday, July 30th. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of Penumbra in a research note on Saturday, September 27th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat, Penumbra currently has an average rating of “Moderate Buy” and an average target price of $302.93.

About Penumbra

Penumbra, Inc, together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.